Establishment of Insulin-Producing Cells From Human Embryonic Stem Cells Underhypoxic Condition for Cell Based
Piyaporn Rattananinsruang1, Chavaboon Dechsukhum2, Wilairat Leeanansaksiri1
1School of Preclinic, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, Thailand.
Abstract:
Diabetes mellitus (DM) is a group of diseases characterized by abnormally high levels of glucose in the blood stream. In developing a potential therapy for diabetic patients, pancreatic cells transplantation has drawn great attention. However, the hinder of cell transplantation for diabetes treatment is insufficient sources of insulin-producing cells. Therefore, new cell based therapy need to be developed. In this regard, human embryonic stem cells (hESCs) may serve as good candidates for this based on their capability of differentiation into various cell types. In this study, we designed a new differentiation protocol that can generate hESC-derived insulin-producing cells (hES-DIPCs) in a hypoxic condition. We also emphasized on the induction of definitive endoderm during embryoid bodies (EBs) formation. After induction of hESCs differentiation into insulin-producing cells (IPCs), the cells obtained from the cultures exhibited pancreas-related genes such as Pdx1, Ngn3, Nkx6.1, GLUT2, and insulin. These cells also showed positive for DTZ-stained cellular clusters and contained ability of insulin secretion in a glucose-dependent manner. After achievement to generated functional hES-DIPCs in vitro, some of the hES-DIPCs were then encapsulated named encapsulated hES-DIPCs. The data showed that the encapsulated cells could possess the function of insulin secretion in a time-dependent manner. The hES-DIPCs and encapsulated hES-DIPCs were then separately transplanted into STZ-induced diabetic mice. The findings showed the significant blood glucose levels regulation capacity and declination of IL-1β concentration in all transplanted mice. These results indicated that both hES-DIPCs and encapsulated hES-DIPCs contained the ability to sustain hyperglycemia condition as well as decrease inflammatory cytokine level in vivo. The findings of this study may apply for generation of a large number of hES-DIPCs in vitro. In addition, the implication of this work is therapeutic value in type I diabetes treatment in the future. The application for type II diabetes treatment remain to be investigated.
Insights
Human embryonic stem cells (hESCs) were differentiated into insulin-producing cells (hES-DIPCs) to treat diabetes. Transplanted hES-DIPCs effectively regulated blood glucose and reduced inflammation in diabetic mice.
Area of Science:
- Stem Cell Biology
- Endocrinology
- Regenerative Medicine
Background:
- Diabetes mellitus (DM) is characterized by hyperglycemia, necessitating effective cell-based therapies.
- Current limitations in diabetes treatment include insufficient sources of insulin-producing cells for transplantation.
- Human embryonic stem cells (hESCs) offer potential due to their differentiation capabilities.
Purpose of the Study:
- To develop a novel differentiation protocol for generating hESC-derived insulin-producing cells (hES-DIPCs).
- To evaluate the functionality and therapeutic potential of hES-DIPCs and encapsulated hES-DIPCs in a mouse model of diabetes.
Main Methods:
- hESCs were differentiated into hES-DIPCs under hypoxic conditions, emphasizing definitive endoderm induction.
- Generated cells were characterized by gene expression (Pdx1, Ngn3, Nkx6.1, GLUT2, insulin) and DTZ staining.
- In vitro insulin secretion assays and in vivo transplantation into STZ-induced diabetic mice were performed.
Main Results:
- Differentiated cells expressed key pancreas-related genes and secreted insulin in a glucose-dependent manner.
- Encapsulated hES-DIPCs maintained insulin secretion over time.
- Transplantation of both hES-DIPCs and encapsulated cells significantly regulated blood glucose and reduced IL-1β levels in diabetic mice.
Conclusions:
- The developed protocol successfully generates functional hES-DIPCs in vitro.
- Both hES-DIPCs and encapsulated hES-DIPCs demonstrate therapeutic potential for managing hyperglycemia and inflammation in vivo.
- This approach holds promise for future type 1 diabetes treatment, with type 2 diabetes applications requiring further investigation.
Related Concept Videos
Embryonic Stem Cells
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Induced Pluripotent Stem Cells
Adult Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...


